• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Network Services opens new U.K. office and expands core services

Clinical Network Services opens new U.K. office and expands core services

March 10, 2014
CenterWatch Staff

Clinical Network Services (CNS), an integrated product development company based in Australia and New Zealand providing services in preclinical, phase I and II trials, has opened a new office near London headed by Paul Cronin, who joins as U.K. director and director, business development. 

The new U.K. office is primarily a BioDesk initiative, and CNS will continue to undertake its core business of conducting early phase clinical trials in Australia and New Zealand, given the simplicity of regulatory review and time advantages for this region. BioDesk is a global product development and regulatory planning consultancy that helps biotech companies advance into the clinic faster through creating and managing a manufacturing and preclinical program that encompasses a globalized regulatory perspective while leveraging regional advantages.

The company also has launched a new biometrics service and has appointed Otto Damsma as director of biometrics and Glynn Morrish as pharmacometrician/biostatistician at its Brisbane headquarters.

Cronin, having worked for European regulatory consultancy companies, is experienced in regulatory affairs and product development, in particular with complex biologics. Cronin also will lead the European BioDesk team supporting CNS clients requiring access to European regulatory agencies as well as European clients seeking entry to Australia and New Zealand. The London location allows for easy access to the EMA and the U.K. MHRA, both based in London.

Damsma led biometrics and IT at Yamanouchi/Astellas in Europe for more than a decade, while Morrish is an Australian pharmacometrician and biostatistician.

Mark Reid, director, BioDesk and regulatory affairs, said, “These appointments have further expanded BioDesk’s ability to engage European regulators and to bring expert statistical and PK/PD modeling capabilities to early stage product development.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing